<<<<why did BMS pass on XL184?>>>>
You have to listen to the R&D day conference recording.
That was one of the questions brought up.
The panel of investigators was talking about the unexpectedly good results, never seen before, etc,,,,,,when someone asked if BMY had access to the same results coming in,,,,why did they pass on XL184???
,,,,The answer was essentially "that's a good question,,,these were open label studies, but that was up to them".
It IS a question for the ages.
I think about this time, EXEL insiders were buying, which is OK since there was a long way to go with the ongoing study.
But, the signal being sent by antedotal cases was certainly enough. BMS really blew it.
Another bio poster elsewhere postulated that BMY is just hard-azzed on making deals at their comfort level whether it be scientific or financial decisions regarding deals? Who knows what was cooking between EXEL and BMY?
I don't know for sure but seems to me they made a collosal mistake unless they buy EXEL out themselves?
Their loss I guess!